Comparing the projected cost per HbA1c reduction of exenatide QW versus liraglutide 1.8 mg for the treatment of type 2 diabetes mellitus using alternate data sources
Abstract
Authors
B. Wang H. Nguyen E. Felber W. Furnback J. Roth L. Garrison